Stem cell research conflict bill moves a step closer to ballot
By Knight Ridder,
Knight Ridder
| 05. 19. 2005
A measure to strengthen conflict-of-interest rules on Proposition 71-funded stem cell research cleared a second legislative hurdle Wednesday, even as critics warned it would scare off scientists.
The bill, SCA13, co-authored by Sens. Deborah Ortiz, D-Sacramento, and George Runner, R-Lancaster, passed the Senate committee on elections on a 5-0 vote. It is due to be considered next in the Senate Appropriations Committee on Monday.
The legislation would require the agency set up by Proposition 71, the measure voters approved in the fall to provide $3 billion toward stem cell research, to follow standards recently applied to the National Institutes of Health.
Those rules forbid employees from holding biotech or pharmaceutical stocks. SCA13 would extend the regulations to the California Institute for Regenerative Medicine, the agency overseeing the research, and its advisory groups.
To become law, the constitutional amendment must receive a two-thirds majority from both houses of the Legislature and be passed by the state's voters.
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...